ILLUMINA, INC. (ILMN) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ILLUMINA, INC.'s filing signal turned negative.

Illumina is a global leader in sequencing and array-based solutions for genetic and genomic analysis, serving research, clinical, and applied markets. Its integrated portfolio of sequencing systems, consumables, and analysis tools enables customers to accelerate and simplify genetic analysis across various complexities and price points. The company's core technologies are based on proprietary reversible terminator-based sequencing chemistry (SBS), with its XLEAP-SBS offering high data accuracy and performance. Illumina's products are utilized in diverse applications, including life sciences research, oncology, reproductive health, and consumer genomics, aiming to advance disease research, drug development, and the creation of molecular diagnostic tests. The company's revenue is predominantly driven by consumables, followed by instruments and services.

Revenue is primarily driven by the sale of consumables, which represented 74% of total consolidated revenue in 2025. Instrument sales accounted for 11% and services and other for 15% of revenue in the same year.